Ken Griffin Rallybio Corp Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.34 - $2.98 $160,347 - $356,592	-119,662 Reduced 29.94%	280,000 $375,000
Q1 2024 May 15, 2024	BUY	$1.25 - $2.4 $101,500 - $194,880	81,200 Added 25.5%	399,662 $739,000
Q4 2023 Feb 14, 2024	BUY	$1.91 - $4.39 $69,726 - $160,261	36,506 Added 12.95%	318,462 $761,000
Q3 2023 Nov 14, 2023	SELL	$3.37 - $6.16 $45,198 - $82,617	-13,412 Reduced 4.54%	281,956 $950,000
Q2 2023 Aug 14, 2023	SELL	$4.31 - $8.89 $249,768 - $515,184	-57,951 Reduced 16.4%	295,368 $1.67 Million
Q1 2023 May 15, 2023	SELL	$4.37 - $8.75 $249 - $498	-57 Reduced 0.02%	353,319 $2.02 Million
Q4 2022 Feb 14, 2023	BUY	$4.67 - $14.86 $1.65 Million - $5.25 Million	353,376 New	353,376 $2.32 Million

31.9M

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $30.5M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.